Table 1.

Patient characteristics, immunologic responses, and antitumor efficacy

IDAge/sexHLAPrimary adenocarcinoma diagnosisBest responseDTH*ElispotELISA
A0158/FDR2,4 A2 B38,62 C6Fallopian tubeProgressionNone+Not detected
A0251/MDR2,3 A2,24 B7,18 C5,7ColonStable 7 mo§Inj 3+Not detected
A0362/MDR2,4 A2,24 B7,60 C3,7LungProgressionInj 3+Not detected
A0462/FDR2,4 A24,29 B45,75 C4,6OesophagusProgressionInj 3+IgM, IgG
A0556/MDR1,2 A1,24 B7,35 C4,6Renal cellProgressionInj 2, 3+Not detected
A0751/FDR1,3 A1,11 B8,35 C4,6BreastProgressionInj 1, 3+Not detected
A08 69/MDR2,7 A2 B7,50 C6,7Renal cellStable 44 moInj 2, 3+IgM, IgG
A09 64/FDR1,3 A1,26 B8,27 C1,7OvaryStable 43 moInj 2, 3+IgG
A1033/FDR11 A1,25 B44,57 C5,6BreastStable 8 mo§Inj 2, 3+IgG
A1170/MDR2,11 A24,30 B51 C15Renal cellProgressionInj 2, 3+Not detected
  • * DTH reactions at the dendritic cells intradermal injection sites are indicated following the specified injection times.

  • Low titer (1/100) anti-VNTR serum antibody reactions or none detectable, measured within 6 months of treatment.

  • Stable or slow progression at study entry and hence not considered to have clinical benefit from dendritic cell-MFP therapy.

  • § Received ongoing dendritic cell-MFP treatment. Overall slow progression (A09) or stable with transient episode of resolving progression (A08).